Taiwan Liposome

What Taiwan Liposome does

Taiwan Liposome Company, now operating as TLC BioSciences (TLC-KY, stock code 7924), is a Taipei-headquartered biopharmaceutical company founded in 1997 by Dr. Hong Ji-Long, a liposome scientist who co-developed the first two FDA-approved liposomal drugs (Doxil and Onivyde) with Demetrios Papahadjopoulos. The company is built around its proprietary LipAD® (Lipid Assembly Drug) platform, which comprises three sub-technologies: BioSeizer® (sustained-release lipid formulations controlling drug release from days to months), NanoX® (targeted delivery with reduced systemic toxicity, including an antibody-conjugated variant), and Genosphere™ (non-viral gene delivery). This core IP has produced three regulatory-approved products and a multi-asset clinical/preclinical pipeline: Ampholipad (liposomal amphotericin B, approved in Taiwan, China 2025, and India), TLC599 (BioSeizer® dexamethasone for knee osteoarthritis, Phase 3 complete), TLC590 (extended-release ropivacaine for post-surgical pain, Phase 3 ongoing targeting 2027 US NDA), TLC518 (once-monthly GLP-1 semaglutide, preclinical), the tLNP in vivo CAR-T platform (preclinical, autoimmune indications), and TLC501/TLC502 preclinical DMOAD candidates. TLC maintains integrated 400-liter GMP manufacturing in Taipei capable of producing over 100,000 units per year with 36+ month stability data.

TLC's business model combines direct commercialization of approved products in Taiwan — distributed through authorized partners including TTY Biopharm and Yung Shin Pharma — with regional out-licensing of pipeline and approved assets to international pharmaceutical companies for upfront, milestone, and royalty payments. Landmark deals include a USD 670 million out-license to Endo International for TLC599 (2022), a Japan out-license for TLC599 valued at over USD 200 million (2026), and a 2025 China commercialization partnership with 3SBio for Ampholipad; past partnerships have also included Teva, Sandoz, and Ablynx. The company operates through wholly-owned subsidiaries in the US (South San Francisco, the operational hub for US clinical and regulatory functions), the Netherlands (Leiden), Japan, Hong Kong, Shanghai, and Australia. Following a going-private transaction in October 2021 that delisted it from NASDAQ and Taiwan OTC, TLC re-listed on Taiwan's emerging stock market in June 2026 at a NT$200 reference price — the highest biotech IPO reference price of 2026 — with the National Development Fund of Taiwan and several large international pharmaceutical companies joining as long-term strategic investors, and a stated cash and equivalents balance of NT$1.769 billion (~USD 550 million) as of May 2026.

Name

Taiwan Liposome

Legal name

Taiwan Liposome Company, Ltd. (台灣微脂體股份有限公司)

Website

https://tlcbio.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

51–100 employees

Short description

TLC BioSciences (Taiwan Liposome) is a Taipei-based clinical-stage biopharmaceutical company that develops and commercializes sustained-release, targeted, and gene-therapy lipid-based drugs via its proprietary LipAD® platform, serving patients in pain, infectious disease, metabolic, and autoimmune indications through direct Taiwan sales and regional out-licensing deals with global pharma partners.

Ownership category

akta.pro rank

Product category

Lipid-based drug delivery pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Lipid drug delivery
• Sustained-release injectables
• Liposomal pharmaceuticals
• Intra-articular osteoarthritis therapy
• In vivo CAR-T therapy

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Product Sales (Direct): Direct sales of approved products in Taiwan and other markets where TLC holds market authorization. Antifungal drug Ampholipad® and anticancer drug are sold in Taiwan via authorized distributors (Tong Yi/Yung Shin), contributing near-term revenue. Ampholipad received marketing approval in China in 2025, with commercialization led by 3SBio.
2. Licensing and Royalty Income: TLC out-licenses pipeline products to international pharmaceutical partners in exchange for upfront payments, development and regulatory milestones, and ongoing royalty payments on net sales. TLC599 was licensed to a Japanese pharmaceutical company for over USD 200 million. Prior deals include a USD 670 million deal with Endo (2022) and multiple partnerships with Teva, Sandoz, Ablynx, and others for various products.
3. Strategic Partnership Milestones: TLC receives milestone payments tied to clinical, regulatory, and commercial achievements as pipeline products advance through development and launch. Examples include USD 670M Endo deal for TLC599 and over USD 200M Japanese licensing deal.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Taiwan Liposome (TLC BioSciences) develops and commercializes pharmaceutical products using its proprietary LipAD® lipid-based drug delivery platform. Its core offerings include the marketed antifungal Ampholipad (liposomal amphotericin B) and clinical-stage candidates TLC599 (intra-articular dexamethasone for knee osteoarthritis) and TLC590 (extended-release ropivacaine for post-surgical pain), along with preclinical assets in metabolic disease (TLC518 once-monthly GLP-1) and in vivo CAR-T cell therapy.

Product overview

TLC BioSciences is a late-stage clinical biopharmaceutical company built on proprietary LipAD® lipid-based drug delivery technology platforms. The portfolio spans three technology platforms (BioSeizer® for sustained release, NanoX® for targeted delivery, and Genosphere™ for gene therapy) and multiple therapeutic areas. Core products include TLC599 (BioSeizer® dexamethasone for knee osteoarthritis pain, Phase 3 complete), TLC590 (ropivacaine extended-release for post-surgical pain, Phase 3 ongoing), TLC518 (once-monthly GLP-1 for obesity/MASH, preclinical), tLNP CAR-T (in vivo CAR-T for autoimmune diseases, preclinical), and marketed Ampholipad (liposomal amphotericin B for fungal infections). The company operates integrated GMP manufacturing capabilities with 400L production scale.

Differentiator

Problem solved

Functional benefit

Brands

• LipAD®: Proprietary lipid drug delivery technology platform enabling nanoscale drug delivery with improved solubility, protection from degradation, and targeted delivery to specific tissues.
• BioSeizer®
• NanoX®
• Genosphere™
• Ampholipad®

Products and services

• TLC599 Proprietary BioSeizer® sustained-release formulation of dexamethasone sodium phosphate for intra-articular injection to treat knee osteoarthritis pain, providing pain relief up to 6 months per injection with potential cartilage-protecting effects.
• TLC590 Ropivacaine extended-release injectable suspension using BioSeizer® sustained-release technology for post-surgical pain management, providing 72+ hours of pain relief with reduced cardiovascular and CNS toxicity versus bupivacaine.
• TLC518 Once-monthly injectable semaglutide formulation using BioSeizer® lipid delivery technology for obesity, MASH, and type 2 diabetes, designed to improve adherence and tolerability versus weekly GLP-1 injections.
• tLNP CAR-T In vivo CAR-T therapy platform using targeted lipid nanoparticles (tLNP) to deliver CAR-encoding mRNA directly to circulating CD8+ T cells, eliminating the need for ex vivo cell manipulation or chemotherapy preconditioning. Targets B-cell-mediated autoimmune diseases including SLE, lupus nephritis, myositis, pemphigus, systemic sclerosis, MS, and myasthenia gravis.
• Ampholipad (TLC166) Liposomal amphotericin B for injection (50 mg), a complex generic version of Gilead's AmBisome® for treatment of life-threatening systemic fungal infections (mucormycosis, aspergillosis, candidiasis, coccidioidomycosis, cryptococcosis). Uses NanoX® technology to reduce kidney toxicity while delivering drug to infection sites. Approved in Taiwan, China, and India.
• TLC501 RNA delivery lipid nanoparticle disease-modifying osteoarthritis drug (DMOAD) combining lipid nanoparticles with RNA to prevent articular tissue degeneration and stimulate regeneration.
• TLC502 Lipid formulation small molecule for cartilage protection and stimulation of chondrogenesis; preclinical stage disease-modifying osteoarthritis drug candidate.

Quantifiable outcome

• TLC599 demonstrated statistically significant pain reduction (WOMAC pain, VAS, and ADP) vs. placebo through 24 weeks in Phase 2 and 52 weeks in Phase 3 (p<0.05). Joint space narrowing was approximately half that of placebo, suggesting structural protection.
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Japanese Pharmaceutical Company (Unnamed)coreOEM/ Whitelabel/ Licensing Partner · 1 June 2026TLC signed a licensing agreement with a Japanese century-old pharmaceutical company for TLC599, providing exclusive rights for development and commercialization in Japan. The deal is valued at over USD 200 million, including upfront payment, development and regulatory milestones, and royalties on net sales. TLC will supply the product while the partner manages Japanese regulatory submissions and commercialization.
• 3SBio (三生製藥)coreChannel Partner/ Reseller/ Distributor · 1 March 20253SBio, a top-50 Chinese pharmaceutical company with RMB 4.389 billion revenue in first-half 2024, leads commercialization of Ampholipad (TLC166) in China following marketing approval from NMPA in March 2025. 3SBio specializes in biopharmaceutical development, manufacturing, and sales, with a top-tier sales force and significant market share in China.
• Endo InternationalcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022TLC signed a USD 670 million licensing deal with Endo Pharmaceuticals for TLC599, setting a record for Taiwan's biotech industry at the time. The deal covered development and commercialization rights in major markets, demonstrating TLC's ability to secure high-value international partnerships.
• Ablynx (Sanofi)minorStrategic or Co-development Partner · 1 January 2014TLC collaborated with Ablynx (a Sanofi company) for the development of targeted anti-cancer drugs combining Ablynx's nanobody technology with TLC's NanoX® drug delivery platform.
• Sandoz (Novartis generic drugs division)minorStrategic or Co-development Partner · 1 January 2013TLC partnered with Sandoz for development and commercialization of products utilizing TLC's proprietary drug delivery technology platforms.
• TTY Biopharm (台耀化學) / Yung Shin Pharma (永信藥品)minorChannel Partner/ Reseller/ Distributor · 1 January 2013TLC partnered with Taiwanese pharmaceutical manufacturers TTY Biopharm and Yung Shin Pharma for the manufacturing and sales of TLC's products in Taiwan, including Ampholipad and anticancer drugs. Both partners hold Taiwan FDA approvals and have established distribution networks.
• Teva PharmaceuticalminorStrategic or Co-development Partner · 1 January 2012TLC entered into a collaboration with Teva, one of the world's largest generic drug companies, to develop and commercialize generic pharmaceutical products leveraging TLC's liposomal drug delivery platform.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Camurus: Swedish specialty pharma developing lipid-based FluidCrystal® sustained-release formulations for CNS, endocrinology, and pain indications - a technology platform peer to TLC's LipAD®/BioSeizer® with comparable regulatory and commercial stages.
• Pacira BioSciences: Pacira is a specialty pharma leader in liposomal/non-opioid sustained-release injectables (Exparel, Zynrelef), directly competing with TLC590 in post-surgical pain and sharing TLC's BioSeizer®-like sustained-release drug delivery focus.

Regional players

• PharmaEngine: Taiwan-listed specialty oncology biotech with similar company stage and regional positioning to TLC, focused on liposomal and nanomedicine oncology drugs with partnership-driven commercialization.
• OBI Pharma: Taiwan-based clinical-stage biopharma developing targeted therapeutics, comparable to TLC in stage, scale, and Taiwan-listed status with similar out-licensing and partnership business model.

Emerging players

• Umoja Biopharma: Umoja is developing in vivo CAR-T platforms using lipid nanoparticle delivery to T-cells, directly comparable to TLC's tLNP CAR-T program in autoimmune disease and oncology indications.
• Capstan Therapeutics: Capstan is a well-funded startup developing targeted lipid nanoparticle (tLNP) technology for in vivo cell engineering, including CAR-T applications in autoimmune disease - a direct technology competitor to TLC's Genosphere™/tLNP platform.
• Luye Pharma Group: China-headquartered specialty pharma with a strong liposomal drug delivery platform (Lipusu, CMNa), making it a direct Asia-Pacific peer in the liposomal pharma space with comparable therapeutic breadth.

Broad incumbents

• Gilead Sciences: Gilead markets AmBisome® (liposomal amphotericin B), the reference product for which TLC's Ampholipad is a complex generic, and operates broadly across antiviral and oncologic liposomal products with overlapping technology.
• Bristol-Myers Squibb: BMS markets Doxil (liposomal doxorubicin), the first FDA-approved liposomal drug that TLC's founder co-developed; represents a major pharma incumbent with liposomal heritage in oncology.
• Ipsen: Ipsen commercializes Onivyde (liposomal irinotecan), one of the world's two FDA-approved liposomal oncology drugs that TLC's founder Dr. Hong helped develop; represents a large-cap liposomal pharma incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/taiwan-liposome-company
• Xx.com/tlcbio
• Facebookfacebook.com/TLCBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taiwan Liposome